ストックスクリーナーアプリを入手
15.90
2.19%
0.34
アフターアワーズ：
15.92
0.02
+0.13%
前日終値:
$15.56
開ける：
$15.7
24時間の取引高:
7.46M
Relative Volume:
0.69
時価総額：
$18.52B
収益：
$14.57B
当期純損益:
$-296.50M
株価収益率:
-61.39
EPS:
-0.259
ネットキャッシュフロー:
$1.64B
1週間 パフォーマンス:
-1.30%
1か月 パフォーマンス:
+4.61%
6か月 パフォーマンス:
+48.25%
1年 パフォーマンス:
+85.10%
1日の値動き範囲:
$15.64
$15.99
1週間の範囲:
$15.50
$16.30
52週間の値動き範囲:
$8.44
$17.53
Viatris Inc Stock (VTRS) Company Profile
Compare VTRS vs TAK, TEVA, HLN, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
15.90 | 18.12B | 14.57B | -296.50M | 1.64B | -0.259 |
TAK
Takeda Pharmaceutical Co Adr
|
15.45 | 47.49B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.43 | 38.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
8.96 | 38.57B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.52 | 32.53B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
547.69 | 23.32B | 3.17B | 1.29B | 1.01B | 27.09 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-09 | アップグレード | UBS | Neutral → Buy |
| 2026-01-16 | アップグレード | Argus | Hold → Buy |
| 2025-12-09 | 開始されました | Barclays | Overweight |
| 2025-10-15 | 開始されました | Truist | Buy |
| 2025-06-06 | 開始されました | Goldman | Neutral |
| 2024-07-19 | 再開されました | Jefferies | Buy |
| 2023-10-23 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2023-06-23 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2023-04-24 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2023-02-17 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | アップグレード | Jefferies | Hold → Buy |
| 2022-11-10 | アップグレード | UBS | Sell → Neutral |
| 2022-11-08 | アップグレード | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | 再開されました | Jefferies | Hold |
| 2022-06-14 | 開始されました | UBS | Sell |
| 2022-05-10 | ダウングレード | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-03-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | 開始されました | Citigroup | Neutral |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2021-03-08 | ダウングレード | Goldman | Buy → Neutral |
| 2021-03-02 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-02-26 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | 開始されました | Argus | Hold |
| 2020-12-14 | 開始されました | Bernstein | Mkt Perform |
すべてを表示
Viatris Inc (VTRS) 最新ニュース
Viatris Inc. stock rises Thursday, outperforms market - MarketWatch
Viatris Inc. stock rises Tuesday, outperforms market - MSN
Salesforce : Agentforce Life Sciences Selected by Viatris as Its Global Customer Engagement Platform - marketscreener.com
Viatris Inc. stock falls Monday, underperforms market - MarketWatch
Viatris Inc. (VTRS) Stock Analysis: Exploring An 11% Potential Upside Amid Mixed Metrics - DirectorsTalk Interviews
Viatris (VTRS) Q4 2025 Earnings Call Transcript - Fortune
Does FDA Review of Fast-Acting Meloxicam Shift Viatris’ (VTRS) Non-Opioid Pain Strategy? - simplywall.st
FDA accepts Viatris' NDA for fast-acting non-opioid pain therapy - MSN
Viatris Inc. stock falls Thursday, underperforms market - MarketWatch
Viatris Top Brass Sued by Investor Over India Facility Problems - Bloomberg Law News
Argus Raises Viatris Price Target to $18 From $15 - Moomoo
Why (VTRS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
VTRS News | VIATRIS INC (NASDAQ:VTRS) - ChartMill
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Tacrolimus Market Research Report 2026: Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2035 - GlobeNewswire Inc.
Viatris Inc. (VTRS) Stock Analysis: Investor Outlook on a Healthcare Giant with an 8.44% Upside Potential - DirectorsTalk Interviews
Assessing Viatris (VTRS) Valuation After FDA Review Acceptance For Fast Acting Non Opioid Meloxicam - Yahoo Finance
Viatris Inc. stock rises Friday, outperforms market - MarketWatch
What Viatris (VTRS)'s Fast-Acting Pain Drug Filing and Profit Uptick Means For Shareholders - simplywall.st
Viatris Inc.: - marketscreener.com
Viatris (VTRS): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
Viatris (VTRS) price target increased by 10.47% to 17.48 - MSN
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
VTRS Maintains Overweight Rating -- Price Target Raised to $22 - GuruFocus
FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy - Yahoo! Finance Canada
Viatris CFO leaving Canonsburg pharma giant - MSN
Barclays Adjusts Price Target on Viatris to $22 From $17, Maintains Overweight Rating - Moomoo
U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain - Sahm
U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Me - GuruFocus
TrumpRx expands into generic medicines (VTRS:NASDAQ) - Seeking Alpha
Viatris rises as Q1 beat indicates growth momentum - MSN
Viatris' Acute Pain Drug NDA Accepted for Review by FDA - Moomoo
5 Revealing Analyst Questions From Viatris’s Q1 Earnings Call - Yahoo Finance
Here's Why Viatris (VTRS) is a Strong Momentum Stock - Yahoo Finance
U.S. FDA accepts Viatris new drug application for fast-acting meloxicam for the treatment of moderate-to-severe acute pain - marketscreener.com
U.S. FDA Accepts Viatris New Drug Application For Fast-Acting Meloxicam For The Treatment Of Moderate-To-Severe Acute Pain - TradingView
Small Cap Opportunities Trust's Viatris Inc(VTRS) Holding History - GuruFocus
FDA accepts Viatris application for fast-acting meloxicam By Investing.com - Investing.com Nigeria
FDA accepts Viatris application for fast-acting meloxicam - Investing.com
Viatris Inc. (VTRS) Stock Analysis: Exploring a 6.19% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Viatris Inc.Common Stock (NQ: VTRS - FinancialContent
Shareholders that lost money on Viatris Inc.(VTRS) should contac - GuruFocus
Viatris Shareholders Approve Directors, Pay and Auditor - The Globe and Mail
Understanding Momentum Shifts in (VTRS) - Stock Traders Daily
Viatris Inc (VTRS) Stock Down 4.5% but Still Overvalued -- GF Sc - GuruFocus
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
Viatris (VTRS) investors elect full board and approve 2025 pay, auditor - Stock Titan
Does Strong Q1 Results And CFO Transition Change The Bull Case For Viatris (VTRS)? - Yahoo Finance
Bacterial Vaginosis Drug Market Will Generate Booming Growth - openPR.com
Viatris Inc (VTRS) 財務データ
収益
当期純利益
現金流量
EPS
1.36%
0.32%
大文字化:
|
ボリューム (24 時間):